Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis

Clinical Pharmacokinetics

Volumn 44, Issue 5, 2005, Pages 539-549

  Novelli, Andrea ^a,b   Adembri, Chiara ^a   Livi, Paola ^a   Fallani, Stefania ^a   Mazzei, Teresita ^a   De Gaudio, Angela Raffaele ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dipartimento di Farmacologia Preclinica e Clinica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG URINE LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEPSIS; URINE VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEPSIS; THIENAMYCINS;

EID: 19544392338     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544050-00007     Document Type: Article

References (36)

1. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51 (1): 99-136
2. Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003: 47 (1): 365-72
3. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 Suppl. A: 207-23
4. Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50 (1): 73-101
5. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 Suppl. A: 311-20
6. Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39 (3): 185-201
7. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997; 28 (4): 157-63
8. Pfaller MA, Jones RN, Biedenbach DJ, et al. Antimicrobials resistance trends in medical centers using carbapenems: report of 1999 and 2000 results of the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001; 41: 177-82
9. White RL, Friedrich LV, Manduru M, et al. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis. Diagn Microbiol Infect Dis 2001; 39 (1): 39-47
10. Nilsson-Ehle I, Hutchison M, Haworth SJ, et al. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991; 10 (2): 85-8
11. Saito A. Pharmacokinetic study on meropenem. Chemotherapy 1992; 40 Suppl. 1: 276-82
12. Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996; 40 (1): 105-9
13. Bush LM, Levison ME. Antibiotic selection and pharmacokinetics in the critically ill. Crit Care Clin 1988; 4 (2): 299-324
14. Neugebauer E, Dietrich A, Lechleuthner A, et al. Pharmacotherapy in shock syndromes: the neglected field of pharmacokinetics and pharmacodynamics. Circ Shock 1992; 36 (4): 312-320
15. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 (6): 1644-55
16. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270 (24): 2957-63
17. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22 (7): 707-10
18. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40 (11): 833-68
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
20. Mazzei T, Tonelli F, Novelli A, et al. Penetration of cefotetan into suction skin blister fluid and tissue homogenates in patients undergoing abdominal surgery. Antimicrob Agents Chemother 1994; 38 (9): 2221-3
21. Novelli A, Mazzei T, Meli E, et al. Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration. J Antimicrob Chemother 1996; 37 (4): 775-81
22. Gibaldi M, Perrier D. Pharmacokinetics. New York (NY): Marcel Dekker, 1982
23. Mouton JW, Vinks AA. Is continuous infusion of β-lactam antibiotics worthwhile: efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38 (1): 5-15
24. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002; 19 (2): 105-10
25. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to Gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999; 29 (3): 595-607
26. Fluit AC, Jones ME, Schmitz FJ, et al. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Antonie Van Leeuwenhoek 2000; 77 (2): 147-52
27. Thalhammer F, Traunmuller F, el Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43 (4): 523-7
28. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115 (3 Suppl.): 19-23S
29. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36 (12): 2577-83
30. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28 (2): 143-60
31. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 Suppl. 1: S39-46
32. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42 (3): 521-7
33. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8 (6): 321-31
34. Tegeder I, Schmidtko A, Brautigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71 (5): 325-33
35. Lam YW, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32 (1): 30-57
36. Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28 (3): 632-7